Systematic Review
. 2007 Jul; 25(21):3158-67.
doi: 10.1200/JCO.2006.08.8823.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

Nicole M Kuderer 1 David C Dale  Jeffrey Crawford  Gary H Lyman  
  • PMID: 17634496
  •     189 citations


Purpose: Randomized controlled trials (RCTs) of prophylactic granulocyte colony-stimulating factors (G-CSF) have demonstrated a significant reduction in febrile neutropenia (FN) after systemic chemotherapy. Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI).

Methods: A comprehensive systematic review and meta-analysis of all reported RCTs comparing primary prophylactic G-CSF with placebo or untreated controls in adult solid tumor and malignant lymphoma patients was undertaken without language restrictions, using electronic databases, conference proceedings, and hand-searching techniques. Two reviewers extracted data independently. Summary estimates of relative risk (RR) with 95% CIs were estimated based on the method of Mantel-Haenszel and DerSimonian and Laird.

Results: Seventeen RCTs were identified including 3,493 patients. For infection-related mortality, RR reduction with G-CSF compared with controls was 45% (RR = 0.55; 95% CI, 0.33 to 0.90; P = .018); for early mortality (all-cause mortality during chemotherapy period), it was 40% (RR = 0.60; 95% CI, 0.43 to 0.83; P = .002); and for FN, it was 46% (RR = 0.54; 95% CI, 0.43 to 0.67; P < .001). Average RDI was significantly higher in patients who received G-CSF compared with control patients (P < .001). Bone or musculoskeletal pain was reported in 10.4% of controls and 19.6% of G-CSF patients (RR = 4.03; 95% CI, 2.15 to 7.52; P < .001). Significant reductions in FN with G-CSF were observed in studies allowing secondary G-CSF prophylaxis in controls and in the three trials with concurrent prophylactic antibiotics in both treatment arms.

Conclusion: Prophylactic G-CSF reduces the risk of FN and early deaths, including infection-related mortality, while increasing RDI and musculoskeletal pain. There are insufficient data to assess the impact of G-CSF on disease-free and overall survival.

Canadian supportive care recommendations for the management of neutropenia in patients with cancer.
C T Kouroukis, S Chia, +4 authors, J Mikhael.
Curr Oncol, 2008 Mar 05; 15(1). PMID: 18317581    Free PMC article.
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
G Stocco, M H Cheok, +8 authors, W E Evans.
Clin Pharmacol Ther, 2008 Aug 08; 85(2). PMID: 18685564    Free PMC article.
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
D Almenar, J Mayans, +8 authors, J Sanchez.
Eur J Cancer Care (Engl), 2008 Dec 17; 18(3). PMID: 19076208    Free PMC article.
Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature.
Nehal Masood, Asim Jamal Shaikh, Wasim Ahmed Memon, Romana Idress.
Cases J, 2008 Dec 26; 1(1). PMID: 19108744    Free PMC article.
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?
Courtney D Fitzhugh, Matthew M Hsieh, +2 authors, John F Tisdale.
Cytotherapy, 2009 Jun 11; 11(4). PMID: 19513902    Free PMC article.
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
Alfredo Carrato, Luis Paz-Ares Rodríguez, +13 authors, Spanish Society of Medical Oncology (SEOM).
Clin Transl Oncol, 2009 Jul 04; 11(7). PMID: 19574202
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.
Ruth Pettengell, Matti Aapro, +5 authors, Jan Walewski.
Clin Drug Investig, 2009 Jul 14; 29(8). PMID: 19591512
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.
S Kelly, D Wheatley.
Br J Cancer, 2009 Sep 17; 101 Suppl 1. PMID: 19756005    Free PMC article.
[Supportive therapy of urogenital tumors: diagnostic and therapy of common complications].
M Bommer, M Kull.
Urologe A, 2009 Oct 13; 48(11). PMID: 19820911
Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens.
Mariangela Manzoni, Sara Delfanti, +5 authors, Marco Danova.
Clin Exp Med, 2009 Oct 13; 10(2). PMID: 19821012
Neoadjuvant chemoradiotherapy, sepsis and neutrophil levels following radical excision of rectal cancer.
Aneel Bhangu, Peter Nightingale, Darren Daniels, Raju Tiramula.
Int J Colorectal Dis, 2010 Feb 24; 25(6). PMID: 20177689
Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.
Wylie Hosmer, Jennifer Malin, Mitchell Wong.
Support Care Cancer, 2010 Feb 25; 19(3). PMID: 20179995    Free PMC article.
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Matti Aapro, Jeffrey Crawford, Didier Kamioner.
Support Care Cancer, 2010 Mar 02; 18(5). PMID: 20191292    Free PMC article.
Non-Hodgkin's lymphoma in the elderly.
Paolo F Caimi, Paul M Barr, Nathan A Berger, Hillard M Lazarus.
Drugs Aging, 2010 Mar 10; 27(3). PMID: 20210368
Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
Alexandre Chan, Wing Hang Fu, +3 authors, Raymond Ng.
Support Care Cancer, 2010 Mar 17; 19(4). PMID: 20232087
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.
Matthias Schwenkglenks, Ruth Pettengell, +5 authors, Robert Leonard.
Support Care Cancer, 2010 Mar 23; 19(4). PMID: 20306092
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
Theresa L Whiteside.
Expert Opin Biol Ther, 2010 Apr 27; 10(7). PMID: 20415597    Free PMC article.
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Cornelius F Waller, Miguel Bronchud, Stuart Mair, Rodeina Challand.
Ann Hematol, 2010 Apr 30; 89(9). PMID: 20428872    Free PMC article.
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.
Jinlu Dai, Yi Lu, +4 authors, Evan T Keller.
Cancer Res, 2010 May 27; 70(12). PMID: 20501834    Free PMC article.
[Comorbidity oriented oncology - an overview].
Ralph Simanek, Michael Wuensch, +3 authors, Klaus Geissler.
Wien Klin Wochenschr, 2010 May 27; 122(7-8). PMID: 20503019
[Hematopoietic growth factors. Possibilities and limitations].
T K Held, M O Hildebrandt, W-D Ludwig.
Internist (Berl), 2010 Jun 15; 51(7). PMID: 20544173
How we treat febrile neutropenia in patients receiving cancer chemotherapy.
Gary H Lyman, Kenneth V I Rolston.
J Oncol Pract, 2010 Sep 03; 6(3). PMID: 20808559    Free PMC article.
Undertreatment of cancer patients with chemotherapy is a global concern.
Gary H Lyman.
J Oncol Pract, 2008 May 01; 4(3). PMID: 20856613    Free PMC article.
ASCO Clinical Practice Guidelines: Past, Present and Future.
Gary H Lyman.
J Oncol Pract, 2008 Sep 01; 4(5). PMID: 20856704    Free PMC article.
Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.
H Sill, W Olipitz, +2 authors, A Wölfler.
Br J Pharmacol, 2010 Nov 03; 162(4). PMID: 21039422    Free PMC article.
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Laetitia Gerlier, Mark Lamotte, +11 authors, Luc Somers.
BMC Cancer, 2010 Nov 26; 10. PMID: 21092320    Free PMC article.
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings.
M Okera, S Chan, +10 authors, S Chowdhury.
Br J Cancer, 2010 Dec 24; 104(3). PMID: 21179036    Free PMC article.
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
A Greystoke, J P B O'Connor, +9 authors, C Dive.
Br J Cancer, 2011 Jan 20; 104(4). PMID: 21245866    Free PMC article.
Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups.
Ruth Pettengell, Matthias Schwenkglenks.
Leuk Lymphoma, 2011 Feb 15; 52(6). PMID: 21314247    Free PMC article.
Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia.
Asim Jamal Shaikh, Samira Ahmed Bawany, +6 authors, Shiyam Kumar.
J Cancer, 2011 Feb 18; 2. PMID: 21326626    Free PMC article.
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation.
Andrea L DiCarlo, Carmen Maher, +6 authors, David M Weinstock.
Disaster Med Public Health Prep, 2011 Mar 22; 5 Suppl 1. PMID: 21402810    Free PMC article.
Treatment of cancer in the older aged person.
Lodovico Balducci.
Mediterr J Hematol Infect Dis, 2010 Jan 01; 2(2). PMID: 21415975    Free PMC article.
Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
Gillian M Keating.
Drugs, 2011 Apr 21; 71(6). PMID: 21504247
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
Gary H Lyman, Nicole M Kuderer, +4 authors, David C Dale.
Cancer, 2011 Apr 22; 117(9). PMID: 21509769    Free PMC article.
Bending the cost curve in cancer care.
Thomas J Smith, Bruce E Hillner.
N Engl J Med, 2011 May 27; 364(21). PMID: 21612477    Free PMC article.
Highly Cited.
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Nicole M Kuderer, Gary H Lyman.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670422    Free PMC article.
Rheumatologic manifestations of benign and malignant haematological disorders.
Vinod Ravindran, Parameswaran Anoop.
Clin Rheumatol, 2011 Jun 24; 30(9). PMID: 21698399
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Nuttapong Ngamphaiboon, Tracey L O'Connor, +2 authors, Ellen B Kossoff.
Med Oncol, 2011 Aug 06; 29(3). PMID: 21818673
Clinical pharmacology of chemotherapy agents in older people with cancer.
Xiaoye He, Stephen J Clarke, Andrew J McLachlan.
Curr Gerontol Geriatr Res, 2011 Aug 17; 2011. PMID: 21845189    Free PMC article.
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Katy L Cooper, Jason Madan, +2 authors, Ron L Akehurst.
BMC Cancer, 2011 Sep 29; 11. PMID: 21943360    Free PMC article.
Systematic Review.
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
Anat Gafter-Gvili, Abigail Fraser, +5 authors, Leonard Leibovici.
Cochrane Database Syst Rev, 2012 Jan 20; 1. PMID: 22258955    Free PMC article.
Systematic Review.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Hematopoietic growth factors: personalization of risks and benefits.
Shannon Puhalla, Saveri Bhattacharya, Nancy E Davidson.
Mol Oncol, 2012 Apr 14; 6(2). PMID: 22497867    Free PMC article.
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
Bradford R Hirsch, Gary H Lyman.
Pharmacoeconomics, 2012 May 01; 30(6). PMID: 22540394
Systematic Review.
SEOM clinical guidelines for myeloid growth factors.
José Muñoz Langa, Pere Gascón, Javier de Castro, SEOM (Spanish Society of Clinical Oncology).
Clin Transl Oncol, 2012 Jun 23; 14(7). PMID: 22721792
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Edgar Petru, Alain Gustave Zeimet, +9 authors, Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).
Wien Klin Wochenschr, 2012 Jun 29; 124(11-12). PMID: 22739650
Costs associated with febrile neutropenia in the US.
Shannon L Michels, Rich L Barron, +3 authors, Gary H Lyman.
Pharmacoeconomics, 2012 Jul 19; 30(9). PMID: 22804805
Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.
X Zhu, N Bouganim, +3 authors, M J Clemons.
Curr Oncol, 2012 Aug 10; 19(4). PMID: 22876152    Free PMC article.
Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.
Nobuaki Ochi, Katsuyuki Hotta, +7 authors, Katsuyuki Kiura.
PLoS One, 2012 Aug 11; 7(8). PMID: 22880112    Free PMC article.
Trends in neutropenia-related inpatient events.
Chris M Kozma, Michael Dickson, +2 authors, Richard Barron.
J Oncol Pract, 2012 Sep 04; 8(3). PMID: 22942808    Free PMC article.
Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.
Marc L Fishman, Akhil Kumar, +2 authors, William J M Hrushesky.
J Oncol Pract, 2012 Sep 04; 8(3 Suppl). PMID: 22942828    Free PMC article.
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Sophie Lee, Angela Knox, +3 authors, Samar Issa.
Support Care Cancer, 2012 Sep 14; 21(3). PMID: 22972488
Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor.
Hiroaki Ohnaka, Hitoshi Tsukamoto, +5 authors, Mikio Masada.
Int J Clin Pharm, 2012 Sep 27; 35(1). PMID: 23011270
Filgrastim improves survival in lethally irradiated nonhuman primates.
Ann M Farese, Melanie V Cohen, +4 authors, Thomas J MacVittie.
Radiat Res, 2012 Dec 06; 179(1). PMID: 23210705    Free PMC article.
Enhancing hematopoietic growth factor performance.
Yen-Michael S Hsu, Daniel C Link.
Nat Med, 2012 Dec 12; 18(12). PMID: 23223059
Supportive therapy in medical therapy of head and neck tumors.
Hartmut Link.
GMS Curr Top Otorhinolaryngol Head Neck Surg, 2013 Jan 16; 11. PMID: 23320053    Free PMC article.
Neutropenia and G-CSF in lymphoproliferative diseases.
Roberto Ria, Antonia Reale, +2 authors, Angelo Vacca.
Hematology, 2013 Jan 17; 18(3). PMID: 23321273    Free PMC article.
Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.
D Almenar Cubells, C Bosch Roig, +8 authors, LEARN II Study Group.
Eur J Cancer Care (Engl), 2013 Jan 22; 22(3). PMID: 23331323    Free PMC article.
Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
Hisaharu Shikata, Yoshihiro Yakushijin, +2 authors, Masaki Yasukawa.
Int J Clin Oncol, 2013 Feb 06; 19(1). PMID: 23380958
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.
Derek Weycker, Oleg Sofrygin, +3 authors, John Edelsberg.
BMC Health Serv Res, 2013 Feb 15; 13. PMID: 23406481    Free PMC article.
The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.
Jean Klastersky, Harry Raftopoulos, Bernardo Rapoport.
Support Care Cancer, 2013 Mar 26; 21(6). PMID: 23525960
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Yukinori Takenaka, Hironori Cho, +3 authors, Hidenori Inohara.
Support Care Cancer, 2013 Jun 12; 21(10). PMID: 23748486
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
G H Lyman, D C Dale, +5 authors, J Crawford.
Ann Oncol, 2013 Jun 22; 24(10). PMID: 23788754    Free PMC article.
Systematic Review.
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Igor Bondarenko, Oleg A Gladkov, +2 authors, Peter Bias.
BMC Cancer, 2013 Aug 16; 13. PMID: 23945072    Free PMC article.
Febrile neutropenia in hematologic malignancies.
Michael K Keng, Mikkael A Sekeres.
Curr Hematol Malig Rep, 2013 Aug 31; 8(4). PMID: 23990311
Influence of endurance exercise on the risk of pneumonia and Fever in leukemia and lymphoma patients undergoing high dose chemotherapy. A pilot study.
Freerk T Baumann, Philipp Zimmer, +3 authors, Thomas Elter.
J Sports Sci Med, 2012 Jan 01; 11(4). PMID: 24150073    Free PMC article.
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Didier Kamioner, Stefan Fruehauf, +3 authors, Christian Berthou.
BMC Cancer, 2013 Nov 19; 13. PMID: 24237790    Free PMC article.
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.
Luigi Rossi, Federica Tomao, +10 authors, Silverio Tomao.
Ther Clin Risk Manag, 2013 Nov 21; 9. PMID: 24255599    Free PMC article.
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice.
S Barni, V Lorusso, +10 authors, P Pronzato.
Med Oncol, 2013 Dec 07; 31(1). PMID: 24307348
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Mi Rim Choi, Craig A Solid, +4 authors, Thomas J Arneson.
Support Care Cancer, 2014 Feb 05; 22(6). PMID: 24492928
Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients.
A Amadio, R Burkes, +2 authors, B Coleman.
Curr Oncol, 2014 Feb 14; 21(1). PMID: 24523621    Free PMC article.
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
J A Pérez-Fidalgo, B Bermejo, +7 authors, A Lluch.
Clin Transl Oncol, 2014 Feb 18; 16(9). PMID: 24532305    Free PMC article.
Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients.
Alexandre Chan, Deren Soh, +2 authors, Joen Chiang.
Support Care Cancer, 2014 Feb 22; 22(7). PMID: 24557010
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Wendy J Langeberg, Conchitina C Siozon, +2 authors, Victoria M Chia.
Support Care Cancer, 2014 Mar 22; 22(8). PMID: 24652049
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
Eva Culakova, Ramya Thota, +5 authors, Gary H Lyman.
Cancer Med, 2014 Apr 08; 3(2). PMID: 24706592    Free PMC article.
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Carlos H Barcenas, Jiangong Niu, +6 authors, Sharon H Giordano.
J Clin Oncol, 2014 May 29; 32(19). PMID: 24868022    Free PMC article.
Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
Martin Smoragiewicz, Khodadad R Javaheri, Yaling Yin, Sharlene Gill.
J Gastrointest Cancer, 2014 Jul 12; 45(4). PMID: 25012517
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Alena M Pfeil, Kim Allcott, +3 authors, Zsolt Szabo.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284721
Systematic Review.
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán, Inmaculada Vallejo-Rodríguez.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284722
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee Schwartzberg.
Cancer Med, 2014 Nov 21; 3(6). PMID: 25410813    Free PMC article.
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Georgia Kourlaba, Meletios A Dimopoulos, +6 authors, Nikos Maniadakis.
Support Care Cancer, 2014 Dec 20; 23(7). PMID: 25524005
Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.
Ranjan Pathak, Smith Giri, +3 authors, Mike G Martin.
Support Care Cancer, 2015 Jan 06; 23(3). PMID: 25556610
Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
Naotaka Nishiyama, Satoshi Takahashi, +4 authors, Naoya Masumori.
Int J Clin Oncol, 2015 Feb 06; 20(5). PMID: 25652906
Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis.
Chun-Wei Wu, Jiunn-Yih Wu, +5 authors, Chien-Chang Lee.
Support Care Cancer, 2015 Feb 24; 23(10). PMID: 25701436
Systematic Review.
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
Norikazu Masuda, Yutaka Tokuda, +3 authors, Kazuo Tamura.
Support Care Cancer, 2015 Mar 04; 23(10). PMID: 25733000    Free PMC article.
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.
Marek Wojtukiewicz, Ewa Chmielowska, +5 authors, Elżbieta Kosno-Kruszewska.
Contemp Oncol (Pozn), 2014 Jan 01; 18(6). PMID: 25784841    Free PMC article.
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Li Wang, Onur Baser, +2 authors, Richard Barron.
Support Care Cancer, 2015 Mar 31; 23(11). PMID: 25821144    Free PMC article.
Systematic Review.
Macrophages support splenic erythropoiesis in 4T1 tumor-bearing mice.
Min Liu, Xing Jin, +3 authors, Yunxue Zhao.
PLoS One, 2015 Mar 31; 10(3). PMID: 25822717    Free PMC article.
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
Tara Arvedson, James O'Kelly, Bing-Bing Yang.
BioDrugs, 2015 May 23; 29(3). PMID: 25998211    Free PMC article.
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
I M Bondarenko, P Bias, A Buchner.
Support Care Cancer, 2015 May 31; 24(1). PMID: 26024743
A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.
Liat Adar, Noa Avisar, +2 authors, Ofer Spiegelstein.
Drug Des Devel Ther, 2015 Jun 02; 9. PMID: 26028962    Free PMC article.
The management of lomustine overdose in malignant glioma patients.
Hans-Georg Wirsching, Isabel Tritschler, +3 authors, Ghazaleh Tabatabai.
Neurooncol Pract, 2015 Jun 03; 1(4). PMID: 26034630    Free PMC article.
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Hartmut Link, J Nietsch, +2 authors, Supportive Care Group (ASORS) of the German Cancer Society (DKG).
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081593
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Chris Skedgel, Daniel Rayson, Tallal Younis.
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081595
Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.
Javier DE Castro Carpeño, Pere Gascón-Vilaplana, +8 authors, Francisco José Rebollo Laserna.
Mol Clin Oncol, 2015 Jul 03; 3(3). PMID: 26137294    Free PMC article.
Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.
H Xu, Q Gong, +2 authors, J H Page.
Support Care Cancer, 2015 Jul 15; 24(2). PMID: 26162536
Understanding the risk for infection in patients with neutropenia.
Jean A Klastersky, Anne-Pascale Meert.
Intensive Care Med, 2015 Jul 15; 42(2). PMID: 26170099
The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.
Eva Culakova, Marek S Poniewierski, +3 authors, Gary H Lyman.
Springerplus, 2015 Aug 08; 4. PMID: 26251780    Free PMC article.
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.
Yasunori Hashiguchi, Mari Kasai, +3 authors, Toshiyuki Sumi.
Anticancer Drugs, 2015 Aug 13; 26(10). PMID: 26267078    Free PMC article.
Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients.
Jordan N Bernens, Kara Hartman, +4 authors, Michael Newton.
J Community Support Oncol, 2015 Aug 20; 13(3). PMID: 26287033    Free PMC article.
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Pere Gascón, Matti Aapro, +6 authors, Ivo Abraham.
Support Care Cancer, 2015 Aug 27; 24(2). PMID: 26306517
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Gilles Freyer, Ewa Kalinka-Warzocha, +9 authors, Zsolt Szabo.
Med Oncol, 2015 Sep 01; 32(10). PMID: 26315712
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Edgar Petru, Christian F Singer, +12 authors, Alain-Gustave Zeimet.
Wien Med Wochenschr, 2015 Oct 17; 165(19-20). PMID: 26471371
Management of infection and febrile neutropenia in patients with solid cancer.
J A Virizuela, J Carratalà, +12 authors, J J Cruz.
Clin Transl Oncol, 2015 Nov 19; 18(6). PMID: 26577106
The importance of the granulocyte-colony stimulating factor in oncology.
Sînziana Cetean, Călin Căinap, +5 authors, Radu Oprean.
Clujul Med, 2016 Jan 07; 88(4). PMID: 26732055    Free PMC article.
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Radosław Mądry, Lidia Popławska, +10 authors, Christine Staudigl.
Wien Klin Wochenschr, 2016 Jan 10; 128(7-8). PMID: 26745973    Free PMC article.
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Ruth Pettengell, Peter Bias, Udo Mueller, Nicole Lang.
Support Care Cancer, 2016 Jan 19; 24(6). PMID: 26780505
Bloodstream infections in patients with solid tumors.
Carlota Gudiol, José María Aguado, Jordi Carratalà.
Virulence, 2016 Jan 21; 7(3). PMID: 26787095    Free PMC article.
Biosimilars in the management of neutropenia: focus on filgrastim.
Désirée Caselli, Simone Cesaro, Maurizio Aricò.
Biologics, 2016 Mar 05; 10. PMID: 26937170    Free PMC article.
Bloodstream infections in neutropenic cancer patients: A practical update.
Giulia Gustinetti, Malgorzata Mikulska.
Virulence, 2016 Mar 24; 7(3). PMID: 27002635    Free PMC article.
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
Chang Gon Kim, Joohyuk Sohn, +8 authors, Gun Min Kim.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27064666    Free PMC article.
A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kohmei Kubo, Yasuhiko Miyazaki, +5 authors, Kazuo Tamura.
Br J Haematol, 2016 Apr 14; 174(4). PMID: 27072050    Free PMC article.
Efficacy and safety of acupuncture for chemotherapy-induced leucopoenia: protocol for a systematic review.
Jiayun Nian, Xu Sun, +6 authors, Ganlin Zhang.
BMJ Open, 2016 May 28; 6(5). PMID: 27231002    Free PMC article.
Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline.
Sarah Mousavi, Mina Dadpoor, Farzaneh Ashrafi.
Int J Hematol Oncol Stem Cell Res, 2016 Jun 03; 10(2). PMID: 27252808    Free PMC article.
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Daphne Y Xiao, Suhong Luo, +6 authors, Kenneth R Carson.
Am J Hematol, 2016 Jul 01; 91(10). PMID: 27356783    Free PMC article.
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
Thomas F Patterson, George R Thompson, +14 authors, John E Bennett.
Clin Infect Dis, 2016 Jul 02; 63(4). PMID: 27365388    Free PMC article.
Highly Cited.
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?
Olga A Martin, Robin L Anderson, Kailash Narayan, Michael P MacManus.
Nat Rev Clin Oncol, 2016 Nov 03; 14(1). PMID: 27550857
Highly Cited. Review.
Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF).
David Schnell, Elie Azoulay, +17 authors, Michael Darmon.
Ann Intensive Care, 2016 Sep 18; 6(1). PMID: 27638133    Free PMC article.
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
M Aapro, H Ludwig, +7 authors, I Abraham.
Ann Oncol, 2016 Oct 30; 27(11). PMID: 27793849    Free PMC article.
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Vicki A Morrison, Edie A Weller, +4 authors, Bruce A Peterson.
Leuk Lymphoma, 2016 Dec 15; 58(8). PMID: 27967294    Free PMC article.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Carsten Bokemeyer, Pere Gascón, +7 authors, Karen MacDonald.
Support Care Cancer, 2017 Jan 24; 25(6). PMID: 28111718    Free PMC article.
Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients.
Jennifer K Hockings, Diwura K Owolabi, Joyce E Broyles, Susan C Wheelis.
Support Care Cancer, 2017 Jan 26; 25(6). PMID: 28120115
Prophylactic Measures During Induction for Acute Myeloid Leukemia.
Matthew W McCarthy, Thomas J Walsh.
Curr Oncol Rep, 2017 Mar 03; 19(3). PMID: 28251490
Filgrastim (G-CSF) loaded liposomes: mathematical modeling and optimization of encapsulation efficiency and particle size.
Farhad Kiafar, Mohammad Reza Siahi Shadbad, Hadi Valizadeh.
Bioimpacts, 2016 Jan 01; 6(4). PMID: 28265535    Free PMC article.
Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
Xiao Jun Wang, Alexandre Chan.
Curr Oncol Rep, 2017 Mar 09; 19(3). PMID: 28271398
Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.
Romina Sosa, Shuling Li, +3 authors, Allan J Collins.
Support Care Cancer, 2017 May 01; 25(10). PMID: 28456908
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Masahiro Yokoyama, Yoshiharu Kusano, +8 authors, Kiyohiko Hatake.
Support Care Cancer, 2017 May 30; 25(11). PMID: 28551843    Free PMC article.
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
T Christopher Bond, Erika Szabo, +5 authors, Boxiong Tang.
J Oncol Pharm Pract, 2017 Jun 16; 24(6). PMID: 28614980    Free PMC article.
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.
Aasthaa Bansal, Sean D Sullivan, +4 authors, Scott D Ramsey.
J Comp Eff Res, 2017 Jul 08; 6(5). PMID: 28686055    Free PMC article.
Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia.
Leszek Kraj, Joanna Krawczyk-Lipiec, Joanna Górniewska, Grzegorz Orlik.
Biomed Rep, 2017 Aug 15; 7(2). PMID: 28804626    Free PMC article.
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
Esse I H Akpo, Irshaad R Jansen, Edith Maes, Steven Simoens.
Front Pharmacol, 2017 Sep 29; 8. PMID: 28955224    Free PMC article.
Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration.
Sadhna O Piryani, Angel Y F Kam, +6 authors, Phuong L Doan.
Stem Cells, 2017 Nov 01; 36(2). PMID: 29086459    Free PMC article.
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.
Peter A Fasching, Lothar Häberle, +19 authors, Liewei Wang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100455    Free PMC article.
Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
Sibylle Schirm, Christoph Engel, +2 authors, Markus Scholz.
J Cancer Res Clin Oncol, 2017 Nov 06; 144(2). PMID: 29103159    Free PMC article.
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Jeffrey J Kirshner, Maxwell C McDonald, +7 authors, Phuong Khanh Morrow.
Support Care Cancer, 2017 Nov 18; 26(4). PMID: 29147854    Free PMC article.
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Isabel Puértolas, Alberto Frutos Pérez-Surio, +2 authors, María Del Tránsito Salvador.
Eur J Clin Pharmacol, 2017 Nov 21; 74(3). PMID: 29152672
The 150 most important questions in cancer research and clinical oncology series: questions 86-93 : Edited by Chinese Journal of Cancer.
Chinese Journal of Cancer.
Chin J Cancer, 2018 Jan 24; 37(1). PMID: 29357949    Free PMC article.
Whom to treat? Factors associated with chemotherapy recommendations and outcomes among patients with NHL at the Uganda Cancer Institute.
Manoj Menon, Anna Coghill, +5 authors, Corey Casper.
PLoS One, 2018 Feb 02; 13(2). PMID: 29389998    Free PMC article.
[Oncological emergencies in chemotherapy : Febrile neutropenia, tumor lysis syndrome, and extravasation].
G von Amsberg.
Urologe A, 2018 Mar 07; 57(5). PMID: 29508029
Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.
Yuko Kanbayashi, Takeshi Ishikawa, +9 authors, Tetsuya Taguchi.
Med Oncol, 2018 Mar 20; 35(4). PMID: 29549536
Medication overuse in oncology: current trends and future implications for patients and society.
Stephen M Schleicher, Peter B Bach, Konstantina Matsoukas, Deborah Korenstein.
Lancet Oncol, 2018 Apr 04; 19(4). PMID: 29611528    Free PMC article.
Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.
Marie Shimanuki, Yorihisa Imanishi, +19 authors, Kaoru Ogawa.
Oncotarget, 2018 May 04; 9(27). PMID: 29721176    Free PMC article.
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.
Chungam Choi, Byung Won Yoo, +5 authors, Min Soo Park.
Drug Des Devel Ther, 2018 Aug 21; 12. PMID: 30122896    Free PMC article.
Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Hassam Baig, Barbara Somlo, +3 authors, Phuong K Morrow.
J Oncol Pharm Pract, 2018 Sep 12; 25(7). PMID: 30200842    Free PMC article.
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.
Lee S Schwartzberg, Lincy S Lal, +4 authors, Stephanie Korrer.
Clinicoecon Outcomes Res, 2018 Sep 15; 10. PMID: 30214262    Free PMC article.
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.
Scott F Huntington, Jessica R Hoag, +8 authors, Amy J Davidoff.
Cancer, 2018 Sep 15; 124(21). PMID: 30216436    Free PMC article.
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
Bernardo Leon Rapoport, Matti Aapro, +4 authors, Jean Klastersky.
BMC Cancer, 2018 Sep 27; 18(1). PMID: 30249215    Free PMC article.
Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Yosuke Morizawa, Makito Miyake, +6 authors, Kiyohide Fujimoto.
Res Rep Urol, 2018 Oct 06; 10. PMID: 30288389    Free PMC article.
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Henri Roché, Jean-Christophe Eymard, +6 authors, Alain Toledano.
BMC Cancer, 2018 Nov 18; 18(1). PMID: 30445935    Free PMC article.
Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data.
Quentin Georges, Elie Azoulay, +16 authors, Michaël Darmon.
Crit Care, 2018 Dec 06; 22(1). PMID: 30514339    Free PMC article.
Systematic Review.
Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.
Kamel Laribi, Delphine Badinand, +5 authors, Rafik Diab.
Support Care Cancer, 2019 Mar 16; 27(11). PMID: 30874925    Free PMC article.
Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.
Hisham Abdel-Azim, Weili Sun, Lingtao Wu.
Pharmacol Ther, 2019 Aug 31; 204. PMID: 31470030    Free PMC article.
Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis.
Yong Wang, Lin Chen, +4 authors, Yong Li.
Sci Rep, 2019 Oct 28; 9(1). PMID: 31653961    Free PMC article.
Systematic Review.
Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia.
Hartmut Link.
Breast Care (Basel), 2019 Dec 05; 14(2). PMID: 31798380    Free PMC article.
A Survey of Oncologists' Perceptions and Opinions Regarding the Use of Granulocyte Colony-Stimulating Factors.
Alicia Hawkins, Alysa Murphy, +3 authors, Michael A Kelsh.
J Cancer Educ, 2019 Oct 28; 35(1). PMID: 31656028    Free PMC article.
Neutrophils Derived from Genetically Modified Human Induced Pluripotent Stem Cells Circulate and Phagocytose Bacteria In Vivo.
Lisa R Trump, Ramesh C Nayak, +4 authors, Jose A Cancelas.
Stem Cells Transl Med, 2019 Feb 23; 8(6). PMID: 30793529    Free PMC article.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Shuling Li, Jiannong Liu, +4 authors, David Chandler.
Support Care Cancer, 2019 Oct 19; 28(6). PMID: 31624920
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
Paul Cornes, Pere Gascon, Arnold G Vulto, Matti Aapro.
BioDrugs, 2020 Apr 02; 34(3). PMID: 32232676    Free PMC article.
Personalized cancer supportive care in COVID-19 era.
G H Lyman, N M Kuderer.
Ann Oncol, 2020 May 15; 31(7). PMID: 32405154    Free PMC article.
Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Prasad L Gawade, Shuling Li, +4 authors, Brian D Bradbury.
Support Care Cancer, 2020 Jan 11; 28(9). PMID: 31919669    Free PMC article.
Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Lee S Schwartzberg, Gajanan Bhat, +9 authors, Patrick Wayne Cobb.
Oncologist, 2020 Jun 02; 25(8). PMID: 32476162    Free PMC article.
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Patrick Wayne Cobb, Yong Wha Moon, +5 authors, Lee S Schwartzberg.
Cancer Med, 2020 Jul 21; 9(17). PMID: 32687266    Free PMC article.
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.
Rolando Innocenti, Luigi Rigacci, +9 authors, Alberto Bosi.
J Blood Med, 2019 Jan 16; 10. PMID: 30643475    Free PMC article.
Machine learning improves the prediction of febrile neutropenia in Korean inpatients undergoing chemotherapy for breast cancer.
Bum-Joo Cho, Kyoung Min Kim, Sanchir-Erdene Bilegsaikhan, Yong Joon Suh.
Sci Rep, 2020 Sep 11; 10(1). PMID: 32908182    Free PMC article.
Predicting neutropenia risk in patients with cancer using electronic data.
Pamala A Pawloski, Avis J Thomas, +3 authors, Gary H Lyman.
J Am Med Inform Assoc, 2016 Sep 18; 24(e1). PMID: 27638907    Free PMC article.
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy.
Ye Won Jeon, Seung Taek Lim, +2 authors, Young Jin Suh.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154827    Free PMC article.
Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.
Jae Hyup Jung, Dong Woo Shin, +2 authors, Jin-Hyeok Hwang.
Cancers (Basel), 2020 Oct 31; 12(11). PMID: 33120908    Free PMC article.
Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
Stephen K Gruschkus, David Lairson, +2 authors, Xianglin L Du.
J Am Geriatr Soc, 2010 Sep 16; 58(10). PMID: 20840455    Free PMC article.
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
John Eckstrom, Trace Bartels, +6 authors, Ali McBride.
Support Care Cancer, 2018 Aug 10; 27(3). PMID: 30090991
Prospective study of a web-mediated management of febrile neutropenia related to chemotherapy (Bioconnect).
Fabrice Denis, Eric Voog, +3 authors, Katell Le Du.
Support Care Cancer, 2018 Oct 12; 27(6). PMID: 30306327
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Derek Weycker, Robin Doroff, +6 authors, Gary H Lyman.
BMC Cancer, 2019 Aug 11; 19(1). PMID: 31399079    Free PMC article.
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Yi Ba, Yuankai Shi, +38 authors, Chenfei Zhou.
Cancer Biol Med, 2020 Dec 11; 17(4). PMID: 33299642    Free PMC article.
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Jean Paul Salmon, Martin Smakal, +5 authors, James O'Kelly.
Support Care Cancer, 2018 Sep 28; 27(4). PMID: 30259136
Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF).
Aylin Yucel, Anne Skalicky, +3 authors, Mark Bensink.
J Patient Rep Outcomes, 2021 Jan 19; 5(1). PMID: 33459887    Free PMC article.
Supportive care in patients with cancer during the COVID-19 pandemic.
M Aapro, G H Lyman, +7 authors, N M Kuderer.
ESMO Open, 2021 Jan 10; 6(1). PMID: 33421735    Free PMC article.
Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.
Aaron B Mendelsohn, James Marshall, +3 authors, Catherine M Lockhart.
Drugs Real World Outcomes, 2021 Feb 01; 8(2). PMID: 33517548    Free PMC article.
Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy.
Ye Won Jeon, Seung Taek Lim, +4 authors, Young Jin Suh.
Ann Surg Treat Res, 2021 Feb 16; 100(2). PMID: 33585350    Free PMC article.
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Ahuva Averin, Amanda Silvia, +8 authors, Derek Weycker.
Support Care Cancer, 2020 Sep 04; 29(4). PMID: 32880732    Free PMC article.
Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
Takashi Ishikawa, Kentaro Sakamaki, +14 authors, for Comprehensive Support Project for Oncological Research of Breast Cancer.
Breast, 2021 Feb 26; 56. PMID: 33631458    Free PMC article.
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer.
Pietro Lapidari, Arnauld Gbenou, +17 authors, Antonio Di Meglio.
Breast, 2021 Mar 13; 57. PMID: 33711699    Free PMC article.
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Masahiro Yokoyama, Yoshiharu Kusano, +5 authors, Yasuhito Terui.
BMC Cancer, 2021 Apr 08; 21(1). PMID: 33823836    Free PMC article.
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Qian Fei, Han-Bo Chen, +3 authors, Song-Wang Chen.
Medicine (Baltimore), 2021 Apr 10; 100(14). PMID: 33832134    Free PMC article.
Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Alberto Marín-Sánchez, Gonzalo Martínez-Fernández, +5 authors, Juan Ramón Romero-Macías.
Ecancermedicalscience, 2021 Apr 30; 15. PMID: 33912231    Free PMC article.
A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Sarah J Zardawi, Ina Nordman, Nicholas Zdenkowski.
Cancer Rep (Hoboken), 2020 Aug 08; 3(5). PMID: 32761893    Free PMC article.
Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
Takahiro Kametani, Yuichiro Otani, +13 authors, Masanori Ito.
Intern Med, 2020 Nov 17; 60(8). PMID: 33191326    Free PMC article.
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Reshma Mahtani, Jeffrey Crawford, +3 authors, Prasad L Gawade.
BMC Cancer, 2021 May 29; 21(1). PMID: 34044798    Free PMC article.
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
Dongling Zou, Mingfang Guo, Qi Zhou.
BMC Cancer, 2021 Jun 04; 21(1). PMID: 34078317    Free PMC article.
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Gary H Lyman, Nicole M Kuderer, Matti Aapro.
Front Oncol, 2021 Jul 27; 11. PMID: 34307165    Free PMC article.